• Engage a patient population that mirrors the epidemiology of the disease studied
• Assure the ecosystem around the trials reflects diverse populations being served. Includes research sites, principal investigators, and extended care teams
• Design in inclusivity from start
• Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials
• Hispanics represent 16% of the US population but only about 3% of clinical trial participants
• In general 80% of patients taking part in clinical trials are white*
• Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition
• Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations
• Data. Better inform treatment decisions by making new options available to patients
• Address disparity and inequity
(1)*CDC Heart Disease Facts https://www.cdc.gov/heartdisease/facts.htm
(2)Cancer Facts & Figures 2020 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
(3)The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity http://cebp.aacrjournals.org/content/25/10/1371
Copyright © 2020 Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program. All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.